Although not dominant, ALK gene amplification has been reported as a resistance mechanism to crizotinib in vitro37 while an amplification of ALK gene has been reported in post-treatment tumor specimens of NSCLC patients8,38. This evidence concerns the gene ALK and non-small cell lung carcinoma.